On August 6th, Rigel Pharmaceuticals (RIGL), reported their Q2 earnings and updates on their flagship product, TAVALISSE. Rigel Pharmaceuticals recorded a beat on EPS of -$0.12 by $0.02 and revenue of $10.41M, which was a beat by $1.13M. It appears that Rigel has been executing with their TAVALISSE sales in chronic ITP, which has experienced a 26% growth in net product sales quarter-over-quarter. Following the earnings release the stock saw an abrupt rise in share price in after-hours; however, the subsequent trading day was a sea of red that quickly subdued the injection